

Supplementary Materials for Consolidated Financial Results for Fiscal Year 2012. 12



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

(Yen)

Fx rates											Forecast
	FY2009	FY2010	FY2011				FY2012				FY2013
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
	(Full-year)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(Full-year)
	average	average	average	average	average	average	average	average	average	average	forecast
CHF	86.20	84.17	87.30	90.38	91.62	89.86	86.01	85.82	84.43	85.12	95.00
EUR	130.10	116.32	112.36	114.86	113.25	110.92	103.91	103.39	101.69	102.59	115.00
USD	93.60	87.81	82.23	81.93	80.55	79.75	79.26	79.71	79.35	79.81	88.00

Financial Highlights (Japan GAAP basis YTD)

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012							
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)
	Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD	
Revenues	428.9	379.5	85.7	181.9	276.0	373.5	90.3	+5.4	185.3	+1.9	275.4	(0.2)	391.2	+4.7
Sales	419.1	375.6	80.4	174.8	267.5	363.6	86.8	+8.0	180.0	+3.0	268.6	+0.4	375.2	+3.2
excl. Tamiflu	342.9	357.4	76.2	170.2	261.2	354.9	79.0	+3.7	171.9	+1.0	260.4	(0.3)	363.2	+2.3
Tamiflu	76.2	18.2	4.2	4.6	6.3	8.7	7.8	+85.7	8.1	+76.1	8.2	+30.2	12.0	+37.9
Ordinary sales	36.2	1.6	3.7	4.1	4.1	5.4	7.5	+102.7	7.8	+90.2	7.9	+92.7	10.2	+88.9
Govt. stockpile etc.	40.0	16.6	0.5	0.5	2.2	3.3	0.4	(20.0)	0.4	(20.0)	0.4	(81.8)	1.9	(42.4)
Other operating revenues	9.8	3.9	5.3	7.2	8.5	9.9	3.5	(34.0)	5.3	(26.4)	6.8	(20.0)	16.0	+61.6
Cost of sales	192.9	162.4	35.1	74.5	115.4	157.5	39.6	+12.8	81.7	+9.7	121.0	+4.9	167.7	+6.5
(% of Sales)	46.0	43.2	43.7	42.6	43.1	43.3	45.6	-	45.4	-	45.0	-	44.7	-
Gross profit	236.1	217.1	50.6	107.4	160.7	216.0	50.6	+0.0	103.5	(3.6)	154.4	(3.9)	223.5	+3.5
(% of Revenues)	55.0	57.2	59.0	59.0	58.2	57.8	56.0	-	55.9	-	56.1	-	57.1	-
SG&A (excl. R&D) expenses	98.2	96.2	22.0	45.3	69.4	97.7	21.0	(4.5)	43.0	(5.1)	66.1	(4.8)	92.0	(5.8)
(% of Revenues)	22.9	25.3	25.7	24.9	25.1	26.2	23.3	-	23.2	-	24.0	-	23.5	-
R&D expenses	55.3	54.7	13.0	26.9	41.2	55.9	13.1	+0.8	26.2	(2.6)	40.0	(2.9)	55.1	(1.4)
(% of Revenues)	12.9	14.4	15.2	14.8	14.9	15.0	14.5	-	14.1	-	14.5	-	14.1	-
Operating income	82.6	66.2	15.6	35.2	50.0	62.4	16.6	+6.4	34.3	(2.6)	48.2	(3.6)	76.4	+22.4
(% of Revenues)	19.3	17.4	18.2	19.4	18.1	16.7	18.4	-	18.5	-	17.5	-	19.5	-
Non-operating income	9.4	2.4	2.1	1.3	3.3	2.3	1.1	(47.6)	1.0	(23.1)	1.2	(63.6)	3.0	+30.4
Non-operating expenses	1.6	3.5	1.0	0.4	2.2	1.2	1.5	+50.0	1.0	+150.0	1.4	(36.4)	4.0	+233.3
Ordinary income	90.4	65.1	16.7	36.2	51.1	63.6	16.3	(2.4)	34.3	(5.2)	48.1	(5.9)	75.4	+18.6
(% of Revenues)	21.1	17.2	19.5	19.9	18.5	17.0	18.1	-	18.5	-	17.5	-	19.3	-
Extraordinary gain	0.3	0.6	-	-	0.0	0.0	0.0	-	0.0	-	0.0	-	0.0	-
Extraordinary loss	1.3	0.0	7.1	7.6	9.1	6.5	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	0.1	(98.5)
Income before income taxes etc.	89.4	65.7	9.6	28.6	42.0	57.1	16.3	+69.8	34.4	+20.3	48.1	+14.5	75.3	+31.9
(% of Revenues)	20.8	17.3	11.2	15.7	15.2	15.3	18.1	-	18.6	-	17.5	-	19.2	-
Net income	56.6	41.4	5.0	17.1	27.1	35.2	9.3	+86.0	20.9	+22.2	29.8	+10.0	48.2	+36.9
(% of Revenues)	13.2	10.9	5.8	9.4	9.8	9.4	10.3	-	11.3	-	10.8	-	12.3	-

Financial Highlights (Japan GAAP basis QTR)

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012							
	1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	428.9	379.5	85.7	96.2	94.1	97.5	90.3	+5.4	95.0	(1.2)	90.1	(4.3)	115.8	+18.8
Sales	419.1	375.6	80.4	94.4	92.7	96.2	86.8	+8.0	93.2	(1.3)	88.6	(4.4)	106.6	+10.8
excl. Tamiflu	342.9	357.4	76.2	94.0	91.0	93.7	79.0	+3.7	92.9	(1.2)	88.5	(2.7)	102.8	+9.7
Tamiflu	76.2	18.2	4.2	0.4	1.7	2.4	7.8	+85.7	0.3	(25.0)	0.1	(94.1)	3.8	+58.3
Ordinary sales	36.2	1.6	3.7	0.4	0.0	1.3	7.5	+102.7	0.3	(25.0)	0.1	–	2.3	+76.9
Govt. stockpile etc.	40.0	16.6	0.5	–	1.7	1.1	0.4	(20.0)	–	–	–	(100.0)	1.5	+36.4
Other operating revenues	9.8	3.9	5.3	1.8	1.4	1.3	3.5	(34.0)	1.8	+0.0	1.5	+7.1	9.2	+607.7
Cost of sales	192.9	162.4	35.1	39.4	40.8	42.1	39.6	+12.8	42.1	+6.9	39.3	(3.7)	46.7	+10.9
(% of Sales)	46.0	43.2	43.7	41.7	44.0	43.8	45.6	–	45.2	–	44.4	–	43.8	–
Gross profit	236.1	217.1	50.6	56.8	53.3	55.4	50.6	+0.0	52.9	(6.9)	50.8	(4.7)	69.1	+24.7
(% of Revenues)	55.0	57.2	59.0	59.0	56.6	56.8	56.0	–	55.7	–	56.4	–	59.7	–
SG&A (excl. R&D) expenses	98.2	96.2	22.0	23.2	24.1	28.3	21.0	(4.5)	22.0	(5.2)	23.1	(4.1)	25.9	(8.5)
(% of Revenues)	22.9	25.3	25.7	24.1	25.6	29.0	23.3	–	23.2	–	25.6	–	22.4	–
R&D expenses	55.3	54.7	13.0	13.9	14.3	14.6	13.1	+0.8	13.2	(5.0)	13.8	(3.5)	15.1	+3.4
(% of Revenues)	12.9	14.4	15.2	14.4	15.2	15.0	14.5	–	13.9	–	15.3	–	13.0	–
Operating income	82.6	66.2	15.6	19.6	14.8	12.4	16.6	+6.4	17.7	(9.7)	13.9	(6.1)	28.2	+127.4
(% of Revenues)	19.3	17.4	18.2	20.4	15.7	12.7	18.4	–	18.6	–	15.4	–	24.4	–
Non-operating income	9.4	2.4	2.1	1.2	2.1	1.9	1.1	(47.6)	1.5	+25.0	0.6	(71.4)	1.7	(10.5)
Non-operating expenses	1.6	3.5	1.0	1.4	2.0	1.8	1.5	+50.0	1.2	(14.3)	0.8	(60.0)	2.6	+44.4
Ordinary income	90.4	65.1	16.7	19.5	14.9	12.5	16.3	(2.4)	18.0	(7.7)	13.7	(8.1)	27.3	+118.4
(% of Revenues)	21.1	17.2	19.5	20.3	15.8	12.8	18.1	–	18.9	–	15.2	–	23.6	–
Extraordinary gain	0.3	0.6	–	–	0.0	0.0	0.0	–	0.0	–	–	–	0.0	–
Extraordinary loss	1.3	0.0	7.1	0.5	1.5	(2.6)	0.0	(100.0)	0.0	(100.0)	0.0	(100.0)	0.1	–
Income before income taxes etc.	89.4	65.7	9.6	19.0	13.4	15.2	16.3	+69.8	18.0	(5.3)	13.7	+2.2	27.3	+79.6
(% of Revenues)	20.8	17.3	11.2	19.8	14.2	15.6	18.1	–	18.9	–	15.2	–	23.6	–
Net income	56.6	41.4	5.0	12.1	10.0	8.1	9.3	+86.0	11.5	(5.0)	9.0	(10.0)	18.4	+127.2
(% of Revenues)	13.2	10.9	5.8	12.6	10.6	8.3	10.3	–	12.1	–	10.0	–	15.9	–

Statements of Revenues (Japan GAAP basis YTD)

(Billions of Yen)

			FY2009	FY2010	FY2011				FY2012							
			1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)
			Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD	
Sales			419.1	375.6	80.4	174.8	267.5	363.6	86.8	+8.0	180.0	+3.0	268.6	+0.4	375.2	+3.2
	Excl. Tamiflu		342.9	357.4	76.2	170.2	261.2	354.9	79.0	+3.7	171.9	+1.0	260.4	(0.3)	363.2	+2.3
		Domestic	309.3	324.4	70.2	150.9	227.8	315.3	68.1	(3.0)	150.4	(0.3)	229.9	+0.9	320.9	+1.8
		Oncology field	123.7	141.2	31.0	67.9	101.5	141.9	32.7	+5.5	72.4	+6.6	111.3	+9.7	156.1	+10.0
		Avastin	34.9	52.6	12.5	26.4	40.2	56.4	13.4	+7.2	29.6	+12.1	46.0	+14.4	65.5	+16.1
		Herceptin	29.7	25.3	5.6	13.9	18.7	25.9	6.1	+8.9	13.5	(2.9)	20.6	+10.2	28.7	+10.8
		Rituxan	21.1	23.0	4.9	10.4	16.2	22.9	5.3	+8.2	11.7	+12.5	17.8	+9.9	24.7	+7.9
		Xeloda	6.6	10.7	2.3	4.9	7.4	10.0	2.4	+4.3	5.2	+6.1	7.9	+6.8	10.9	+9.0
		Tarceva	5.8	7.9	1.7	3.8	5.8	8.3	1.9	+11.8	4.5	+18.4	6.9	+19.0	9.5	+14.5
		Neutrogen	11.3	10.4	1.8	4.1	6.6	9.4	1.8	+0.0	4.0	(2.4)	6.2	(6.1)	8.8	(6.4)
		Femara	2.4	3.2	0.8	1.7	2.6	3.6	0.8	+0.0	1.9	+11.8	2.9	+11.5	4.1	+13.9
		Kytril	8.6	5.5	0.8	1.7	2.5	3.4	0.6	(25.0)	1.2	(29.4)	1.8	(28.0)	2.4	(29.4)
		Other products	3.3	2.5	0.5	1.0	1.5	2.1	0.4	(20.0)	0.8	(20.0)	1.2	(20.0)	1.7	(19.0)
		Bone and joint diseases field	57.6	62.6	14.0	30.4	47.2	66.2	13.6	(2.9)	30.3	(0.3)	46.9	(0.6)	66.3	+0.2
		Actemra	8.4	14.1	3.5	7.6	12.1	17.5	3.8	+8.6	7.9	+3.9	12.1	+0.0	17.1	(2.3)
		Evista	17.9	18.7	3.8	8.4	13.2	18.5	3.4	(10.5)	7.6	(9.5)	11.6	(12.1)	16.1	(13.0)
		Suvenyl	13.7	13.6	2.6	6.0	9.3	13.0	2.7	+3.8	5.9	(1.7)	9.0	(3.2)	12.3	(5.4)
		Alfarol	13.6	12.3	2.6	5.4	8.2	11.2	2.2	(15.4)	4.4	(18.5)	6.2	(24.4)	8.1	(27.7)
		Edirol *	-	-	-	0.6	0.8	1.3	0.6	-	2.5	+316.7	4.8	+500.0	7.9	+507.7
		Other products	3.9	4.0	1.5	2.4	3.6	4.6	0.9	(40.0)	1.9	(20.8)	3.2	(11.1)	4.7	+2.2
		Renal diseases field	61.0	57.4	11.4	24.3	36.9	50.7	10.3	(9.6)	22.9	(5.8)	34.8	(5.7)	48.1	(5.1)
		Mircera *	-	-	-	-	2.8	5.9	3.0	-	7.5	-	12.2	+335.7	17.8	+201.7
		Epogin	44.4	40.0	7.5	16.6	22.5	28.8	3.9	(48.0)	7.7	(53.6)	11.1	(50.7)	14.5	(49.7)
		Oxarol	10.6	12.0	2.8	5.8	8.8	12.2	2.7	(3.6)	5.9	+1.7	8.9	+1.1	12.3	+0.8
		Renagel	5.3	4.9	1.1	1.7	2.3	3.1	0.6	(45.5)	1.5	(11.8)	2.3	+0.0	3.1	+0.0
		Other products	0.7	0.5	0.1	0.2	0.4	0.7	0.1	+0.0	0.2	+0.0	0.4	+0.0	0.4	(42.9)
		Transplant, Immunology & Infectious diseases field	26.2	25.8	5.5	11.5	17.0	22.8	4.5	(18.2)	9.8	(14.8)	14.8	(12.9)	20.3	(11.0)
		Pegasys	11.1	10.5	2.2	4.4	6.3	8.3	1.6	(27.3)	3.4	(22.7)	5.1	(19.0)	6.9	(16.9)
		Copegus	4.9	4.5	0.9	1.9	2.6	3.3	0.5	(44.4)	1.0	(47.4)	1.5	(42.3)	2.0	(39.4)
		CellCept	4.4	5.2	1.2	2.6	4.1	5.7	1.4	+16.7	3.1	+19.2	4.7	+14.6	6.5	+14.0
		Other products	5.8	5.7	1.2	2.6	4.0	5.5	1.1	(8.3)	2.3	(11.5)	3.5	(12.5)	4.9	(10.9)
		Others field	40.9	37.4	8.3	16.8	25.2	33.8	6.9	(16.9)	15.0	(10.7)	22.2	(11.9)	30.1	(10.9)
		Sigmar	14.7	13.0	2.7	5.7	8.3	11.1	2.2	(18.5)	4.7	(17.5)	6.9	(16.9)	9.5	(14.4)
		Other products	26.3	24.4	5.6	11.0	16.9	22.6	4.8	(14.3)	10.3	(6.4)	15.3	(9.5)	20.5	(9.3)
		Overseas	33.6	33.0	5.9	19.3	33.4	39.6	10.9	+84.7	21.5	+11.4	30.5	(8.7)	42.3	+6.8
		Actemra	8.9	12.7	1.4	9.1	18.8	20.5	6.8	+385.7	13.4	+47.3	18.2	(3.2)	25.6	+24.9
		Neutrogen	21.3	17.0	3.5	8.1	11.7	15.6	3.4	(2.9)	6.7	(17.3)	10.3	(12.0)	13.9	(10.9)
		Sigmar	1.9	2.2	0.6	1.2	1.7	2.1	0.3	(50.0)	0.6	(50.0)	0.9	(47.1)	1.4	(33.3)
		Other products	1.5	1.2	0.5	0.9	1.2	1.4	0.4	(20.0)	0.8	(11.1)	1.1	(8.3)	1.4	+0.0
		Tamiflu	76.2	18.2	4.2	4.6	6.3	8.7	7.8	+85.7	8.1	+76.1	8.2	+30.2	12.0	+37.9
		Ordinary sales	36.2	1.6	3.7	4.1	4.1	5.4	7.5	+102.7	7.8	+90.2	7.9	+92.7	10.2	+88.9
		Govt. stockpile etc.	40.0	16.6	0.5	0.5	2.2	3.3	0.4	(20.0)	0.4	(20.0)	0.4	(81.8)	1.9	(42.4)
Other operating revenues			9.8	3.9	5.3	7.2	8.5	9.9	3.5	(34.0)	5.3	(26.4)	6.8	(20.0)	16.0	+61.6
Revenues (total)			428.9	379.5	85.7	181.9	276.0	373.5	90.3	+5.4	185.3	+1.9	275.4	(0.2)	391.2	+4.7
		Domestic	392.6	342.9	77.7	159.0	237.8	327.9	78.1	+0.5	161.1	+1.3	240.8	+1.3	341.3	+4.1
		Overseas	36.4	36.6	8.0	22.9	38.2	45.6	12.2	+52.5	24.2	+5.7	34.6	(9.4)	49.9	+9.4

Note: Edirol (launched in April 2011), Mircera (launched in July 2011)

Statements of Revenues (Japan GAAP basis QTR)

(Billions of Yen)

			FY2011				FY2012							
			FY2009	FY2010										
			1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)
			Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR	
Sales			419.1	375.6	80.4	94.4	92.7	96.2	86.8	+8.0	93.2	(1.3)	88.6	(4.4)
	Excl. Tamiflu		342.9	357.4	76.2	94.0	91.0	93.7	79.0	+3.7	92.9	(1.2)	88.5	(2.7)
	Domestic		309.3	324.4	70.2	80.6	76.9	87.5	68.1	(3.0)	82.3	+2.1	79.5	+3.4
		Oncology field	123.7	141.2	31.0	36.8	33.7	40.4	32.7	+5.5	39.7	+7.9	38.9	+15.4
		Avastin	34.9	52.6	12.5	13.9	13.8	16.2	13.4	+7.2	16.1	+15.8	16.4	+18.8
		Herceptin	29.7	25.3	5.6	8.3	4.8	7.2	6.1	+8.9	7.3	(12.0)	7.1	+47.9
		Rituxan	21.1	23.0	4.9	5.5	5.8	6.7	5.3	+8.2	6.3	+14.5	6.1	+5.2
		Xeloda	6.6	10.7	2.3	2.6	2.5	2.7	2.4	+4.3	2.8	+7.7	2.7	+8.0
		Tarceva	5.8	7.9	1.7	2.1	2.0	2.4	1.9	+11.8	2.6	+23.8	2.4	+20.0
		Neutrogin	11.3	10.4	1.8	2.3	2.5	2.8	1.8	+0.0	2.3	+0.0	2.2	(12.0)
		Femara	2.4	3.2	0.8	0.9	0.9	1.0	0.8	+0.0	1.1	+22.2	1.0	+11.1
		Kytril	8.6	5.5	0.8	0.9	0.8	0.9	0.6	(25.0)	0.6	(33.3)	0.6	(25.0)
		Other products	3.3	2.5	0.5	0.5	0.5	0.5	0.4	(20.0)	0.5	+0.0	0.4	(20.0)
		Bone and joint diseases field	57.6	62.6	14.0	16.4	16.8	19.0	13.6	(2.9)	16.7	+1.8	16.6	(1.2)
		Actemra	8.4	14.1	3.5	4.1	4.5	5.4	3.8	+8.6	4.2	+2.4	4.2	(6.7)
		Evista	17.9	18.7	3.8	4.6	4.8	5.3	3.4	(10.5)	4.2	(8.7)	3.9	(18.8)
		Suvenyl	13.7	13.6	2.6	3.4	3.3	3.7	2.7	+3.8	3.2	(5.9)	3.0	(9.1)
		Alfarol	13.6	12.3	2.6	2.8	2.8	3.1	2.2	(15.4)	2.2	(21.4)	1.8	(35.7)
		Edirol	—	—	—	0.6	0.2	0.5	0.6	—	1.9	+216.7	2.3	+1,050.0
		Other products	3.9	4.0	1.5	0.9	1.2	1.0	0.9	(40.0)	1.0	+11.1	1.4	+16.7
		Renal diseases field	61.0	57.4	11.4	12.9	12.6	13.8	10.3	(9.6)	12.5	(3.1)	11.9	(5.6)
		Mircera	—	—	—	—	2.8	3.1	3.0	—	4.5	—	4.6	+64.3
		Epogin	44.4	40.0	7.5	9.1	6.0	6.3	3.9	(48.0)	3.8	(58.2)	3.4	(43.3)
		Oxarol	10.6	12.0	2.8	3.0	3.0	3.4	2.7	(3.6)	3.2	+6.7	3.0	+0.0
		Renagel	5.3	4.9	1.1	0.7	0.6	0.7	0.6	(45.5)	0.9	+28.6	0.8	+33.3
		Other products	0.7	0.5	0.1	0.1	0.2	0.3	0.1	+0.0	0.1	+0.0	0.1	(50.0)
		Transplant, Immunology & Infectious diseases field	26.2	25.8	5.5	6.0	5.4	5.8	4.5	(18.2)	5.3	(11.7)	5.0	(7.4)
		Pegasys	11.1	10.5	2.2	2.3	1.9	2.0	1.6	(27.3)	1.8	(21.7)	1.7	(10.5)
		Copegus	4.9	4.5	0.9	1.0	0.7	0.7	0.5	(44.4)	0.6	(40.0)	0.4	(42.9)
		CellCept	4.4	5.2	1.2	1.4	1.4	1.6	1.4	+16.7	1.6	+14.3	1.6	+14.3
		Other products	5.8	5.7	1.2	1.4	1.4	1.5	1.1	(8.3)	1.2	(14.3)	1.2	(14.3)
		Others field	40.9	37.4	8.3	8.4	8.4	8.5	6.9	(16.9)	8.1	(3.6)	7.2	(14.3)
		Sigmart	14.7	13.0	2.7	3.0	2.6	2.8	2.2	(18.5)	2.5	(16.7)	2.2	(15.4)
		Other products	26.3	24.4	5.6	5.4	5.9	5.7	4.8	(14.3)	5.6	+3.7	4.9	(16.9)
		Overseas	33.6	33.0	5.9	13.4	14.1	6.3	10.9	+84.7	10.6	(20.9)	9.0	(36.2)
		Actemra	8.9	12.7	1.4	7.7	9.7	1.7	6.8	+385.7	6.6	(14.3)	4.8	(50.5)
		Neutrogin	21.3	17.0	3.5	4.6	3.6	3.9	3.4	(2.9)	3.3	(28.3)	3.6	+0.0
		Sigmart	1.9	2.2	0.6	0.6	0.5	0.4	0.3	(50.0)	0.3	(50.0)	0.3	(40.0)
		Other products	1.5	1.2	0.5	0.4	0.3	0.3	0.4	(20.0)	0.4	+0.0	0.3	+0.0
		Tamiflu	76.2	18.2	4.2	0.4	1.7	2.4	7.8	+85.7	0.3	(25.0)	0.1	(94.1)
		Ordinary sales	36.2	1.6	3.7	0.4	0.0	1.3	7.5	+102.7	0.3	(25.0)	0.1	—
		Govt. stockpile etc.	40.0	16.6	0.5	—	1.7	1.1	0.4	(20.0)	—	—	—	(100.0)
Other operating revenues			9.8	3.9	5.3	1.8	1.4	1.3	3.5	(34.0)	1.8	+0.0	1.5	+7.1
Revenues (total)			428.9	379.5	85.7	96.2	94.1	97.5	90.3	+5.4	95.0	(1.2)	90.1	(4.3)
	Domestic		392.6	342.9	77.7	81.3	78.8	90.1	78.1	+0.5	83.0	+2.1	79.7	+1.1
	Overseas		36.4	36.6	8.0	14.9	15.3	7.4	12.2	+52.5	12.0	(19.5)	10.4	(32.0)

Balance Sheets (Japan GAAP basis)

(Billions of Yen)

	FY2009	FY2010	FY2011				FY2012				
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	vs. Dec. 31, 2011
Cash and deposits	107.0	76.2	101.7	109.2	110.7	107.2	123.1	130.0	97.1	110.9	+3.7
Trade notes and accounts receivable	121.6	113.4	94.6	105.8	98.4	110.9	94.6	99.5	99.8	120.0	+9.1
Marketable securities	52.2	59.7	58.0	59.0	59.0	61.0	67.0	71.0	101.0	101.0	+40.0
Inventories	92.6	104.9	108.5	110.4	115.7	105.0	101.2	99.4	101.3	108.9	+3.9
Other current assets	37.9	32.3	39.7	27.6	33.9	35.4	35.1	31.0	33.8	34.9	(0.5)
Total Current assets	411.3	386.5	402.5	412.1	417.7	419.4	421.1	430.8	433.0	475.7	+56.3
Property, plant and equipment	93.7	88.0	86.1	83.5	81.8	82.9	80.9	81.9	82.2	82.3	(0.6)
Intangible assets	3.2	2.4	2.3	2.4	2.1	2.0	1.9	1.7	1.7	1.7	(0.3)
Investments and other assets	32.3	31.2	29.3	31.3	32.8	29.2	28.5	27.7	27.3	28.0	(1.2)
thereof Investment securities	9.7	7.6	7.0	6.9	6.9	6.4	6.6	6.0	5.8	6.2	(0.2)
Total Noncurrent Assets	129.2	121.5	117.8	117.3	116.7	114.1	111.4	111.3	111.1	112.0	(2.1)
Total Assets	540.5	508.0	520.3	529.4	534.4	533.5	532.5	542.2	544.1	587.7	+54.2
Trade notes and accounts payable	34.3	19.5	29.5	28.5	29.2	17.4	23.9	26.8	29.2	41.7	+24.3
Short-term loans and bonds	–	–	–	–	–	–	–	–	–	–	–
Other current liabilities	66.2	35.1	42.4	40.3	48.1	51.5	42.3	40.6	41.4	49.9	(1.6)
Total current liabilities	100.5	54.6	72.0	68.8	77.3	68.8	66.2	67.3	70.6	91.6	+22.8
Long-term debt and bonds	–	–	–	–	–	–	–	–	–	–	–
Other noncurrent liabilities	5.4	4.0	5.3	5.3	5.4	5.6	5.5	5.5	5.8	6.0	+0.4
Total noncurrent liabilities	5.4	4.0	5.3	5.3	5.4	5.6	5.5	5.5	5.8	6.0	+0.4
Total liabilities	105.9	58.6	77.3	74.1	82.8	74.4	71.7	72.8	76.4	97.6	+23.2
Common stock	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	–
Capital surplus	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	–
Retained earnings	308.0	327.6	320.1	332.2	331.4	339.5	338.0	349.6	347.6	366.0	+26.5
Treasury stock, at cost	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.3)	(36.2)	(36.2)	(36.1)	+0.2
Net unrealized gain or loss on securities	1.6	1.3	1.0	0.9	1.1	0.8	1.6	1.4	1.3	1.6	+0.8
Deferred gains or losses on hedges	–	–	–	–	–	–	0.3	(0.2)	0.0	0.1	+0.1
Foreign currency translation adjustments	(6.8)	(11.3)	(9.5)	(9.7)	(12.2)	(13.0)	(10.9)	(13.3)	(13.0)	(9.7)	+3.3
Subscription rights to shares	0.5	0.8	0.8	0.9	0.9	1.0	1.1	1.1	1.2	1.2	+0.2
Minority interests	1.8	1.4	1.0	1.4	1.0	1.2	1.1	1.2	0.9	1.2	0.0
Total net assets	434.7	449.4	443.0	455.3	451.6	459.1	460.8	469.4	467.7	490.1	+31.0
Total liabilities and net assets	540.5	508.0	520.3	529.4	534.4	533.5	532.5	542.2	544.1	587.7	+54.2

Cash Flows (Japan GAAP basis)

(Billions of Yen)

	FY2009		FY2010		FY2011				FY2012			
	1-12	1-12	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	Full-year	Full-year	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
Net cash provided by (used in) operating activities	66.5	15.6	39.6	50.2	67.8	69.6	34.0	50.3	62.2	77.3		
Net cash provided by (used in) investing activities	(20.3)	(20.2)	(0.8)	(3.7)	(6.4)	(15.1)	(8.8)	(15.9)	(51.5)	(54.8)		
Net cash provided by (used in) financing activities	(22.3)	(23.1)	(13.2)	(13.2)	(24.3)	(24.6)	(11.1)	(11.3)	(22.5)	(22.7)		
Effect of exchange rate changes on cash and cash equivalents	(0.1)	(1.7)	0.7	0.6	(0.7)	(0.6)	0.7	(0.1)	0.1	1.1		
Net increase (decrease) in cash and cash equivalents	23.8	(29.3)	26.4	34.0	36.5	29.3	14.9	23.0	(11.8)	0.9		
Cash and cash equivalents at beginning of period	70.7	94.5	65.1	65.1	65.1	65.1	94.5	94.5	94.5	94.5		
Cash and cash equivalents at end of period	94.5	65.1	91.6	99.1	101.7	94.5	109.4	117.5	82.7	95.4		

Performance Indicators (Japan GAAP basis)

	FY2009		FY2010		FY2011				FY2012				IFRS Core basis
	1-12	1-12	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2013
	As of Dec. 31	As of Dec. 31	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Net income per share (Basic)	104.00yen	76.14yen	9.17yen	31.40yen	49.85yen	64.75yen	17.17yen	38.39yen	54.83yen	88.58yen			–
Net income per share (Fully diluted) *1	103.98yen	76.12yen	9.17yen	31.39yen	49.84yen	64.73yen	17.16yen	38.37yen	54.81yen	88.54yen			–
Ratio of net income to shareholders' equity *2	13.7%	9.4%	1.1%	3.8%	6.0%	7.8%	2.0%	4.5%	6.5%	10.2%			–
Ratio of ordinary income to total assets *2	17.7%	12.4%	3.2%	7.0%	9.8%	12.2%	3.1%	6.4%	8.9%	13.5%			–
Net assets per share	794.51yen	821.87yen	810.62yen	832.45yen	826.39yen	839.50yen	842.68yen	858.26yen	855.58yen	896.02yen			–
Equity ratio	80.0%	88.0%	84.8%	85.6%	84.2%	85.6%	86.1%	86.2%	85.6%	83.0%			–
Dividend per share (Annual)	40yen	40yen				40yen				40yen			45yen
Dividend per share (Interim)	17yen	17yen				20yen				20yen			22yen
Dividend payout ratio (Consolidated)	38.5%	52.5%				61.8%				45.2%			48.6%

Notes: 1. "Accounting Standard for Earnings Per Share" (Accounting Standards Board of Japan (ASBJ) Statement No. 2, revised on June 30, 2010) and "Guidance on Accounting Standard for Earnings Per Share" (ASBJ Guidance No. 4, revised on June 30, 2010) are applied to the amounts for FY2011 and FY2012.

2. Quarterly (year-to-date) Ratio of net income to shareholders' equity and Ratio of ordinary income to total assets are not annualized.

3. Dividend payout ratio (Consolidated) for FY2013 is calculated on an IFRS (core basis)

Number of Employees

	FY2009		FY2010		FY2011				FY2012			
	1-12	1-12	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	As of Dec. 31	As of Dec. 31	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31
Number of employees	6,485	6,709	6,635	6,818	6,812	6,779	6,760	6,886	6,863	6,836		

Note: Number of employees doesn't include staff seconded to companies outside the Group.

Capital Expenditures (Japan GAAP basis)

(Billions of Yen)

	FY2009		FY2010		FY2011				FY2012				IFRS basis
	1-12	1-12	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	Forecast
	Full-year	Full-year	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	FY2013
Capital expenditures	14.6	12.7	1.4	4.6	6.4	11.9	1.2	5.7	10.0	14.2			15.5
Depreciation	19.5	18.0	3.8	7.2	11.4	15.9	3.5	7.1	11.1	15.3			13.5

Note: Capital expenditures & Depreciation for FY2013 are forecasted on an IFRS basis

Major Capital Investments Plan

(The Company)

(Billions of Yen)

Facilities (Location)	Description	Planned investment		Fund raising method	Start of construction	Slated completion date
		Total amount	Investment to-date			
Ukima area (Kita-ku, Tokyo)	Improvement of investigational drug building for biologics	2.2	2.0	Self-financing	May 2011	October 2013

(Domestic Subsidiaries)

None

Commitment Line (Loan Framework) Contract

(Billions of Yen)

	Amount
Total Commitments	40.0
Commitments used	–
Commitments unused	40.0

Note: The Company maintains commitment line contracts with nine financial institutions.

Financial Highlights (IFRS basis YTD)

(Billions of Yen)

	Pro forma	Pro forma			
	FY2011	FY2012			
	1-12	1-3	1-6	1-9	1-12
	YTD	YTD	YTD	YTD	YTD
Revenues	372.1	90.3	185.5	275.6	386.6
Sales	363.5	86.8	180.1	268.6	375.2
excl. Tamiflu	354.7	79.0	171.9	260.4	363.2
Domestic	315.1	68.1	150.5	229.9	320.9
Sales to Roche	20.5	6.8	13.4	18.2	25.6
Overseas	19.2	4.1	8.1	12.3	16.7
Tamiflu	8.7	7.8	8.1	8.2	12.0
Ordinary sales	5.4	7.5	7.8	7.9	10.2
Govt. stockpile etc.	3.3	0.4	0.4	0.4	1.9
Royalties and other operating income	8.6	3.5	5.4	7.0	11.3
Cost of sales	(161.9)	(39.6)	(81.7)	(121.3)	(168.2)
(% of Sales)	(44.5)	(45.6)	(45.4)	(45.2)	(44.8)
Gross profit	210.2	50.7	103.7	154.3	218.4
(% of Revenues)	56.5	56.1	55.9	56.0	56.5
Operating expenses	(150.7)	(32.9)	(67.3)	(103.5)	(143.7)
(% of Revenues)	(40.5)	(36.4)	(36.3)	(37.6)	(37.2)
Marketing & distribution expenses	(69.0)	(15.4)	(32.2)	(48.7)	(67.9)
(% of Revenues)	(18.5)	(17.1)	(17.4)	(17.7)	(17.6)
Research & development expenses	(70.5)	(15.8)	(31.1)	(48.3)	(66.6)
(% of Revenues)	(18.9)	(17.5)	(16.8)	(17.5)	(17.2)
General & administration expenses	(11.2)	(1.7)	(4.0)	(6.4)	(9.2)
(% of Revenues)	(3.0)	(1.9)	(2.2)	(2.3)	(2.4)
Operating profit	59.4	17.9	36.4	50.8	74.7
(% of Revenues)	16.0	19.8	19.6	18.4	19.3
Financial income	2.2	(0.4)	(1.2)	(1.3)	(1.9)
Financing costs	(1.1)	(0.0)	(0.0)	(0.0)	(0.0)
Profit before taxes	60.6	17.5	35.2	49.5	72.7
(% of Revenues)	16.3	19.4	19.0	18.0	18.8
Income taxes	(18.0)	(6.6)	(13.1)	(18.1)	(25.8)
Net income	42.6	10.9	22.0	31.4	46.8
(% of Revenues)	11.4	12.1	11.9	11.4	12.1
Attributable to					
-Chugai shareholders	41.6	10.7	21.6	30.7	46.1
-Non-controlling interests	1.0	0.2	0.4	0.6	0.8
Earnings per share					
Basic (Yen)	76.37	19.68	39.75	56.48	84.62
Diluted (Yen)	76.34	19.67	39.73	56.46	84.58

2011 & 2012 results are Non-Audited (Pro forma)

Financial income includes net amount of FX related gains/losses.

The revised IAS19 Employee Benefits is retrospectively applied to FY2012 results

Financial Highlights (IFRS Core basis YTD)

(Billions of Yen)

	Pro forma	Pro forma					Core Forecast (Jan 30th Announced)	
	FY2011	FY2012					FY2013	
	1-12	1-3	1-6	1-9	1-12	1-12	1-12	Change(%)
	YTD	YTD	YTD	YTD	YTD	YTD	YTD	
Revenues	372.1	90.3	185.5	275.6	386.6	416.0	+7.6	
Sales	363.5	86.8	180.1	268.6	375.2	394.3	+5.1	
excl. Tamiflu	354.7	79.0	171.9	260.4	363.2	385.5	+6.1	
Domestic	315.1	68.1	150.5	229.9	320.9	329.3	+2.6	
Sales to Roche	20.5	6.8	13.4	18.2	25.6	40.6	+58.6	
Overseas	19.2	4.1	8.1	12.3	16.7	15.6	(6.6)	
Tamiflu	8.7	7.8	8.1	8.2	12.0	8.8	(26.7)	
Ordinary sales	5.4	7.5	7.8	7.9	10.2	8.1	(20.6)	
Govt. stockpile etc.	3.3	0.4	0.4	0.4	1.9	0.8	(57.9)	
Royalties and other operating income	8.6	3.5	5.4	7.0	11.3	21.7	+92.0	
Cost of sales	(156.8)	(39.4)	(81.3)	(120.6)	(167.3)	(183.2)	+9.5	
(% of Sales)	(43.1)	(45.4)	(45.1)	(44.9)	(44.6)	(46.5)	—	
Gross profit	215.3	50.9	104.2	155.0	219.3	232.8	+6.2	
(% of Revenues)	57.9	56.4	56.2	56.2	56.7	56.0	—	
Operating expenses	(149.5)	(32.8)	(67.3)	(103.5)	(143.7)	(155.3)	+8.1	
(% of Revenues)	(40.2)	(36.3)	(36.3)	(37.6)	(37.2)	(37.3)	—	
Marketing & distribution expenses	(68.4)	(15.4)	(32.2)	(48.7)	(67.9)			
(% of Revenues)	(18.4)	(17.1)	(17.4)	(17.7)	(17.6)			
Research & development expenses	(70.5)	(15.8)	(31.1)	(48.3)	(66.6)			
(% of Revenues)	(18.9)	(17.5)	(16.8)	(17.5)	(17.2)			
General & administration expenses	(10.6)	(1.7)	(4.0)	(6.4)	(9.2)			
(% of Revenues)	(2.8)	(1.9)	(2.2)	(2.3)	(2.4)			
Operating profit	65.8	18.1	36.9	51.5	75.6	77.5	+2.5	
(% of Revenues)	17.7	20.0	19.9	18.7	19.6	18.6	—	
Financial income	2.2	(0.4)	(1.2)	(1.3)	(1.9)			
Financing costs	(1.1)	(0.0)	(0.0)	(0.0)	(0.0)			
Profit before taxes	66.9	17.7	35.6	50.2	73.6			
(% of Revenues)	18.0	19.6	19.2	18.2	19.0			
Income taxes	(20.6)	(6.6)	(13.3)	(18.4)	(26.2)			
Net income	46.4	11.1	22.3	31.8	47.4			
(% of Revenues)	12.5	12.3	12.0	11.5	12.3			
Attributable to								
—Chugai shareholders	45.3	10.9	21.9	31.2	46.6			
—Non-controlling interests	1.0	0.2	0.4	0.6	0.8			
Core earnings per share (diluted) (Yen)	83.27	19.93	40.25	57.24	85.64	92.57	+8.1	
Core payout ratio (%)	48.0%	—	—	—	46.7%	48.6%	—	

Core results are Non-Audited (Pro forma). Please refer to “Notice concerning adoption of International Financial Reporting Standards (IFRS) “
<http://www.chugai-pharm.co.jp/html/press/pdf/2012/121214eSupplementaryMaterials.pdf> page 11–13 for the detail of IFRS (core basis).
 Financial income includes net amount of FX related gains/losses.
 The revised IAS19 Employee Benefits is retrospectively applied to FY2012 results

Statements of Revenues (IFRS basis YTD)

(Billions of Yen)

	Pro forma FY2011 1-12 Full-year	Pro forma FY2012				Forecast (Jan 30th announced) FY2013	
		1-3 YTD	1-6 YTD	1-9 YTD	1-12 YTD	1-12 Full-year	Change (%)
Sales	363.5	86.8	180.1	268.6	375.2	394.3	+5.1
Excl. Tamiflu	354.7	79.0	171.9	260.4	363.2	385.5	+6.1
Domestic	315.1	68.1	150.5	229.9	320.9	329.3	+2.6
Oncology field	141.8	32.7	72.4	111.3	156.1	175.4	+12.4
Avastin	56.3	13.4	29.6	46.0	65.5	76.6	+16.9
Herceptin	25.9	6.1	13.5	20.6	28.7	30.4	+5.9
Rituxan	22.9	5.3	11.7	17.8	24.7	26.3	+6.5
Xeloda	10.0	2.4	5.2	7.9	10.9	13.9	+27.5
Tarceva	8.3	1.9	4.5	6.9	9.5	11.0	+15.8
Neutrogen	9.4	1.8	4.0	6.2	8.8	9.4	+6.8
Other products	9.1	1.8	4.0	5.9	8.2	7.8	(4.9)
Bone and joint diseases field	66.1	13.6	30.3	46.9	66.3	54.3	(18.1)
Actemra	17.5	3.8	7.9	12.1	17.1	19.1	+11.7
Evista	18.5	3.4	7.7	11.6	16.1	—	(100.0)
Suvenyl	12.9	2.7	5.9	9.0	12.3	13.2	+7.3
Alfarol	11.2	2.2	4.4	6.2	8.1	6.7	(17.3)
Edirol	1.3	0.6	2.6	4.8	7.9	11.0	+39.2
Other products	4.6	0.9	1.9	3.2	4.7	4.3	(8.5)
Renal diseases field	50.6	10.3	22.9	34.8	48.1	52.0	+8.1
Mircera	5.9	3.0	7.5	12.2	17.8	28.2	+58.4
Epogin	28.8	3.9	7.7	11.1	14.5	8.6	(40.7)
Oxarol	12.2	2.7	5.9	8.9	12.3	12.7	+3.3
Other products	3.8	0.8	1.7	2.6	3.6	2.5	(30.6)
Transplant, Immunology & Infectious diseases field	22.8	4.5	9.8	14.8	20.3	18.1	(10.8)
Pegasys	8.3	1.6	3.4	5.1	6.9	5.7	(17.4)
Copegus	3.3	0.5	1.0	1.5	2.0	1.2	(40.0)
CellCept	5.7	1.4	3.1	4.7	6.5	6.7	+3.1
Other products	5.5	1.1	2.3	3.5	4.9	4.5	(8.2)
Others field	33.7	6.9	15.0	22.2	30.1	29.6	(1.7)
Sigmart	11.1	2.2	4.7	6.9	9.5	8.9	(6.3)
Other products	22.6	4.8	10.3	15.3	20.5	20.6	+0.5
Overseas	39.7	10.9	21.5	30.5	42.3	56.1	+32.6
Actemra	20.5	6.8	13.4	18.2	25.6	40.8	+59.4
To Roche	20.5	6.8	13.4	18.2	25.6	40.6	+58.6
Neutrogen	15.6	3.4	6.7	10.3	13.9	13.2	(5.0)
Other products	3.5	0.7	1.4	2.0	2.8	2.2	(21.4)
Tamiflu	8.7	7.8	8.1	8.2	12.0	8.8	(26.7)
Ordinary sales	5.4	7.5	7.8	7.9	10.2	8.1	(20.6)
Govt. stockpile etc.	3.3	0.4	0.4	0.4	1.9	0.8	(57.9)
Royalties and other operating income	8.6	3.5	5.4	7.0	11.3	21.7	+92.0
Revenues (total)	372.1	90.3	185.5	275.6	386.6	416.0	+7.6
Domestic	327.8	78.1	161.2	240.9	338.0	349.0	+3.3
Overseas	44.3	12.2	24.2	34.7	48.6	67.0	+37.9

2011 & 2012 results are Non-Audited (Pro forma)

Development pipeline (as of January 30, 2013)

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Oncology</u>					
RG1273 (RO4368451)	Breast cancer	Filed (12/05)	pertuzumab	Roche Perjeta	HER dimerization inhibitory humanized monoclonal antibody
	Breast cancer (adjuvant)	Phase III Multinational study	Injection		
RG1415 (RO50-8231)	Non-small cell lung cancer (1st line) #	Filed (12/06)	erlotinib HCl Tarceva Oral	Roche / OSI Tarceva	EGFR tyrosine kinase inhibitor
RG435 (RO4876646)	Recurrent glioblastoma #	Filed (12/09)	bevacizumab Avastin Injection	Roche Avastin	Anti-VEGF(Vascular Endothelial Growth Factor) humanized monoclonal antibody
	Ovarian cancer #	Filed (12/10)			
	Glioblastoma #	Phase III Multinational study			
	Breast cancer (adjuvant) #	Phase III Multinational study			
RG3502 (RO5304020)	Breast cancer	Filed (13/01)	trastuzumab emtansine	Roche	Anti-HER2 antibody-drug conjugate (T-DM1)
	Gastric cancer	Phase II / III Multinational study			
RG3638 (RO5490258/ PRO143966)	Non-small cell lung cancer	Phase III Multinational study	onartuzumab Injection	Roche	Humanized anti-Met monoclonal antibody (MetMAB)
GA101 / RG7159 (RO5072759)	Indolent NHL	Phase III Multinational study	obinutuzumab Injection	Roche (Nippon Shinyaku)	Glycoengineered type II anti-CD20 monoclonal antibody
	Aggressive NHL	Phase III Multinational study			
GC33 / RG7686 (GC33/RO5137382)	Liver cancer	Phase II Multinational study	Injection	In-house	Humanized anti-Glypican-3 monoclonal antibody
				(Roche)	
RG340 (RO09-1978)	Gastric cancer (adjuvant) #	Phase II	capecitabine Xeloda Oral	Roche Xeloda (Yakult Honsha)	Antimetabolite, 5-FU derivative

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
AF802 / RG7853 (CH5424802)	Non-small cell lung cancer	Phase I / II	Oral	In-house (Roche)	ALK inhibitor
		Phase I / II Overseas			
RG7204 (RO5185426)	Melanoma	Phase I / II	vemurafenib Oral	Roche Zelboraf	BRAF inhibitor
WT4869 (WT4869)	Myelodysplastic syndromes	Phase I / II	Injection	In-house / Dainippon Sumitomo Pharma	WT1 peptide cancer vaccine
	Solid tumors	Phase I			
WT2725 (WT2725)	Advanced cancer	Phase I Overseas	Injection	In-house / Dainippon Sumitomo Pharma	WT1 peptide cancer vaccine
CIF / RG7167 (RO4987655)	Solid tumors	Phase I	Oral	In-house (Roche)	MEK inhibitor
		Phase I Overseas			
CKI27 / RG7304 (RO5126766)	Solid tumors	Phase I	Oral	In-house (Roche)	Raf and MEK dual inhibitor
		Phase I Overseas			
PA799 (CH5132799)	Solid tumors	Phase I Overseas	Oral	In-house	PI3K class I inhibitor
<u>Bone and Joint Diseases</u>					
RG484 (Ro200-5450iv) (Ro200-5450po)	Osteoporosis	Filed (12/07)	ibandronate sodium hydrate Injection	Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical)	Bisphosphonate
		Phase III	ibandronate sodium hydrate Oral		
NRD101 (NRD101)	Enthesopathy (Lateral epicondylitis, Patellar tendinitis, Achilles tendinopathy, Plantar fasciitis)	Phase III	sodium hyaluronate Suvenyl Injection	In-house	Sodium hyaluronate

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Autoimmune Diseases</u>					
MRA (MRA-SC)	Rheumatoid arthritis (new formulation: subcutaneous injection)	Filed (12/03)	tocilizumab Actemra / RoActemra(EU) Injection	In-house (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
		Filed (12/12) Overseas			
SA237 (SA237)	Rheumatoid arthritis	Phase I	Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody
RG7415 (PRO155767)	Systemic lupus erythematosus (SLE)	Phase I	rontalizumab Injection	Roche	Humanized anti-interferon alpha monoclonal antibody
<u>Diabetes Mellitus</u>					
CSG452 (CSG452)	Type II diabetes	Phase III	tofogliflozin hydrate Oral	In-house (Kowa, Sanofi)	SGLT2 inhibitor
<u>Central Nervous System</u>					
RG1678 (RO4917838)	Schizophrenia	Phase III Multinational study	bitopertin Oral	Roche	Glycine reuptake inhibitor
RG7090 (RO4917523)	Major depressive disorder	Phase II Multinational study	Oral	Roche	mGluR5 antagonist
RG1450 (RO4909832)	Alzheimer's disease	Phase I	gantenerumab Injection	Roche/MorphoSys	Human anti-amyloid-beta monoclonal antibody
<u>Respiratory Diseases</u>					
RG3637 (RO5490255)	Asthma	Phase I Overseas	lebrikizumab Injection	Roche	Humanized anti-IL-13 monoclonal antibody

Development code (Compound number)	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
Others					
CIM331 (CIM331)	Atopic dermatitis	Phase I	Injection	In-house	-
ACE910 (ACE910)	Hemophilia A	Phase I	Injection	In-house	Anti-factor IXa x anti-factor X humanized bispecific antibody
RG7652	Hyperlipidemia	Phase I Overseas	Injection	Roche	Human anti-PCSK9 monoclonal antibody

Changes from the last announcement on October 23, 2013

Oncology

-RG435
-RG3502
-GA101

Phase III → Development suspended (Gastric cancer)
Phase III multinational study → Filed (Breast cancer)
Agreement with Nippon Shinyaku Co. Ltd., to co-develop and co-market

Diabetes Mellitus

-CSG452

License agreement with Kowa Company, Ltd. and Sanofi K.K.

Others

-RG7652

Phase I (Hyperlipidemia: Starting development)

R&D Activities (Jan. 1, 2012 – Jan. 30, 2013)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- In April 2012, we started a Phase III multinational study (expected indication: breast cancer (adjuvant)) for a humanized HER dimerization inhibitory monoclonal antibody, RG1273. In addition, a new drug application for a expected indication of breast cancer was submitted in May, 2012.
- In June 2012, we filed an application for an additional indication of non-small cell lung cancer (1st line therapy) for the EGFR tyrosine kinase inhibitor, Tarceva (RG1415).
- We filed an application for additional indication of an anti-VEGF humanized monoclonal antibody, RG435 (product name: Avastin) for recurrent glioblastoma in September, and for ovarian cancer in October 2012. The application for an additional indication of gastric cancer was removed from the pipeline chart as clinical evaluation of efficacy for the intended indication was found difficult.
- In September 2012, we started a Phase II/III multinational study (expected indication: gastric cancer) for a HER2 antibody-drug conjugate, RG3502. In addition, a new drug application for an expected indication of breast cancer was submitted in January, 2013.
- In November 2012, we started a Phase III multinational study (expected indication: non-small cell lung cancer) for a humanized anti-Met monoclonal antibody, RG3638.
- In November 2012, we entered into a license agreement with Nippon Shinyaku Co., Ltd., to co-develop and co-market glycoengineered type II anti-CD20 monoclonal antibody GA101.
- In March 2012, we started a Phase II multinational study (expected indication: liver cancer) for a humanized anti-Glypican-3 monoclonal antibody, GC33 (RG7686).
- In July 2012, we started a Phase II study (additional indication: gastric cancer (adjuvant)) for a 5-FU derivative, Xeloda (RG340).
- In September 2012, we started a Phase I study (expected indication: melanoma) for a BRAF inhibitor, RG7204.
- A recombinant human erythropoietin, EPOCH (product name: Epogin) (additional indication: chemotherapy induced anemia) was removed from the pipeline chart following the receipt of the unapproval letter in October 2011. We will continue to review options for resubmission.
- We decided to terminate the development of a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra) for an additional indication of pancreatic cancer (improvements of the systematic symptoms and prognosis for the patients with unresectable pancreatic cancer) as efficacy and safety evaluation of the drug for the intended indication was found difficult.

Bone and Joint Diseases

- In July 2012, we filed a new drug application for a bisphosphonate, RG484 (Injection), for an expected indication of osteoporosis. In addition, in October 2012, we started a Phase III study (expected indication: osteoporosis) for a bisphosphonate, RG484 (Oral).

Autoimmune diseases

- In March 2012, we filed an application for a new formulation (subcutaneous formulation) of a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra/ RoActemra) for rheumatoid arthritis.
- In July 2012, we started Phase I study (expected indication: systemic lupus erythematosus) for a humanized anti-interferon alpha monoclonal antibody (RG7415).

Diabetes Mellitus

- In October, we entered into a license agreement with Kowa Company, Ltd. and Sanofi K.K.. Under the agreement, the three companies will co-develop the compound, and Kowa and Sanofi will file the application for marketing authorization, while Chugai will manufacture the products for supply to the two

companies.

Central Nervous System

- In September 2012, we started a Phase II multinational study (expected indication: major depressive disorder) for an mGluR5 antagonist, RG7090.

Others

- In August 2012, we started Phase I study (expected indication: Hemophilia A) for an anti-factor IXa x anti-factor X humanized bispecific antibody, ACE910.

Also, as for development activities overseas, the Company saw progress as described below:

- In May 2012, we started Phase I/II study (expected indication: non-small cell lung cancer) for an ALK inhibitor, AF802.
- In August 2012, we started Phase I study (expected indication: advanced cancer) for a WT1 peptide cancer vaccine, WT2725.
- In April 2012, we obtained an approval for a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra/ RoActemra), for rheumatoid arthritis in Korea. In addition, in October 2012, Roche obtained an approval for expanded indication of rheumatoid arthritis (DMARDs-IR) in US. Furthermore, in December 2012, applications for a new dosage form (subcutaneous formulation) for rheumatoid arthritis indication were submitted in US and EU.
- In October 2012, we started Phase I study (expected indication: Hyperlipidemia) for a human anti-PCSK9 monoclonal antibody, RG7652.

Major clinical trials in oncology field currently running in Japan

Theme	Expected Indication	Regimen	Stage	Planned Filing Date
RG1273 (pertuzumab)	Breast cancer (1st line)	RG597 + docetaxel ± RG1273	Filed in May 2012	-
	Breast cancer (adjuvant)	RG597 + chemotherapy ± RG1273	APHINITY study Phase III multinational study	Post 2016
RG1415 (erlotinib HCL) Tarceva	Non-small cell lung cancer (1st line)	RG1415	Filed in Jun. 2012	-
RG435 (bevacizumab) Avastin	Recurrent glioblastoma	RG435	Filed in Sep. 2012	-
	Glioblastoma (1st line)	temozolomide ± RG435	AVAglio study Phase III multinational study	2014
	Breast cancer (adjuvant)	standard chemotherapy ± RG435	BEATRICE study Phase III multinational study	2015
RG3502 (trastuzumab emtansine)	Breast cancer (1st line)	RG3502 ± RG1273	MARIANNE study Phase III multinational study	-
	Breast cancer (2nd line)	RG3502	Filed in Jan. 2013	
	Gastric cancer	RG3502 vs chemotherapy	Phase II / III multinational study	2015
GA101/ RG7159 (obinutuzumab)	Indolent NHL	GA101 + chemotherapy vs rituximab + chemotherapy (G-chemo vs R-chemo)	GALLIUM study Phase III multinational study	Post 2016
	Aggressive NHL	GA101 + CHOP vs rituximab + CHOP (G-CHOP vs R-CHOP)	GOYA study Phase III multinational study	Post 2016

Theme	Expected Indication	Regimen	Stage	Planned Filing Date
RG340 (capecitabine) Xeloda	Gastric cancer (adjuvant)	RG340 + oxaliplatin	Phase II	2014
RG3638 (onartuzumab)	Non-small cell lung cancer (2nd line or later)	RG3638 ± erlotinib	MetLung study Phase III multinational study	2015